08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the optimism is...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

Amturnide regulatory update

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Amturnide   Business: Cardiovascular   FDA approved an NDA from Novartis for Amturnide to treat hypertension in patients not adequately controlled on 2 medications. Amturnide is a single-pill combination...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Trickle-down effect

Although companies in the $1-$1.9 billion market cap range were the big winners for 2010 with a 28% gain, last quarter saw gains migrate into lower rungs of the market cap ladder. Small caps with $200-$499...
01:28 , Dec 23, 2010 |  BC Extra  |  Company News

FDA approves Amturnide for hypertension

FDA approved an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for Amturnide to treat hypertension in patients not adequately controlled on two medications. Amturnide is a single-pill combination of three drugs: Tekturna aliskiren, amlodipine and hydrochlorothiazide....